Vibrent Health is set to join a hybrid/remote decentralised clinical research study funded by the Biomedical Advanced Research and Development Authority (BARDA).
The company is partnering with the Fred Hutch Cancer Center in this regard, under a $17m contract awarded via the BARDA’s Rapid Response Partnership Vehicle (RRPV) consortium.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The initiative aims to improve research into correlates of protection (CoPs), notably measurable immune markers predicting protective immunity, through decentralised clinical trials (DCTs).
Traditional clinical trials often require participants to visit sites, which may limit enrolment. Supported by Vibrent Health, the new approach focuses on bringing research directly to participants through decentralised and patient-centric digital engagement tools.
It enables real-world data integration and remote biospecimen collection, thereby increasing access and supporting rapid scientific progress.
Vibrent Health’s participation in the BARDA-funded project shows how hybrid decentralised studies can enhance infectious disease research by enabling broader participation and richer data collection.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe underlying data management platform used by Vibrent Health centralises patient-reported outcomes, biospecimen details, electronic case report forms, and operational metrics to enhance transparency for researchers and clinical staff.
It also provides advanced dashboards for real-time tracking of trial metrics such as adverse event monitoring and enrolment rates. Dynamic visualisations support group-specific data analysis for study teams.
The scalable model used in the trial applies to commercial studies across therapeutic areas, including neuroscience, metabolic disorders, precision medicine, oncology, and others.
The platform is available for biopharma sponsors, contract research organisations (CRO), and academic research organisations seeking integrated solutions for decentralised or hybrid trials.
Vibrent Health CEO Praduman Jain said: “This research represents a pivotal step in understanding how the immune system responds to vaccines through the use of real-world data collected remotely. By identifying correlates of protection in a large population, we can drive innovation to improve public health preparedness for future infectious disease outbreaks.”
